Resources Repository
-
ArticlePublication 2022WHO ACTION-I Trial in Low Resource Countries
This study evaluated the cost-effectiveness of dexamethasone administration in dexamethasone in pregnant women at risk …
This study evaluated the cost-effectiveness of dexamethasone administration in dexamethasone in pregnant women at risk of early preterm birth using data from a multicentre, randomized, placebo-controlled trial in Bangladesh, India, Kenya, Nigeria, and Pakistan. Primary cost data were collected in 28 hospitals across the 5 countries. A decision tree model was used to compare dexamethasone treatment to no intervention from a health-care sector perspective. Administration of dexamethasone averted 38 neonatal deaths per 1000 woman–baby units…
Health Outcomes | Asia & Pacific | Sub-Saharan Africa | Clinical Care | Mathematical Models | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Global -
ArticlePublication 2021Individual and Social Determinants of COVID-19 Vaccine Uptake
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using …
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using national survey data collected before vaccines were available in the U.S. Of note, individuals under the federal poverty level and racial and ethnic minorities were oversampled. Outcomes included the likelihood of vaccinating self and dependents (e.g., children). Independent variables included perceptions of risk, exposure to different media for COVID-19 news, political party identification, confidence in scientists and social determinants of…
Health Outcomes | North America | Clinical Care | Infectious Diseases | Evidence Synthesis | Social Determinants | Policy/Regulation | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Health Outcomes | Asia & Pacific | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Middle East & North Africa -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Health Outcomes | Asia & Pacific | Sub-Saharan Africa | Infectious Diseases | State-Transition | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Economics/Finance | Health/Medicine | Middle East & North Africa | Latin America & Caribbean -
OrganizationWeb Portal 2024PATH
PATH is an international nonprofit organization that has been translating ideas into health solutions for …
PATH is an international nonprofit organization that has been translating ideas into health solutions for 40 years, with a focus on child survival, maternal and reproductive health, and infectious diseases. PATH mobilizes partners around the world in order to take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. PATH takes a multidimensional approach to solving health challenges, with work spanning five platforms: Vaccines to give children a…
Health Outcomes | Asia & Pacific | Sub-Saharan Africa | Infectious Diseases | Costing Methods | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Social Determinants | Health Systems | Health/Medicine | Global -
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Health Outcomes | Asia & Pacific | Sub-Saharan Africa | Infectious Diseases | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment | Economics/Finance | Health/Medicine | Global -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Health Outcomes | North America | Clinical Care | Infectious Diseases | Preferences/Values | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Culture/Society | Health/Medicine | Science/Technology | Europe -
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Health Outcomes | Asia & Pacific | Clinical Care | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Health Outcomes | Asia & Pacific | Sub-Saharan Africa | Infectious Diseases | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine | Global | Middle East & North Africa | Latin America & Caribbean